Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
In patients with distal and medium vessel occlusion strokes, tenecteplase achieves higher early recanalization rates and reduces early infarct growth compared to alteplase, supporting its preferential use in this clinical setting.
Secondary analysis of the TASTE trial reveals tenecteplase confers superior functional outcomes versus alteplase in patients with distal middle cerebral artery occlusions, supporting its use in more peripheral ischemic stroke territories.
The ENCHANTED trial post hoc analysis reveals body weight does not alter alteplase dose effectiveness in acute ischemic stroke, but low body weight independently predicts poorer outcomes without increased hemorrhagic risk.
In a randomized trial of large-vessel-occlusion stroke, standard-dose tenecteplase improved early reperfusion before thrombectomy compared with low-dose alteplase, with similar safety and functional outcomes.
In patients with large-vessel-occlusion stroke undergoing thrombectomy, standard-dose tenecteplase achieved more early reperfusion than low-dose alteplase, with similar safety and functional outcomes.
This review analyzes the ICSM Phase III study, highlighting how a structured empowerment program and standardized protocols in EMS significantly reduced prehospital delays and tripled alteplase administration rates for acute ischemic stroke
An IPD meta-analysis of six randomized trials (2313 patients) found IV alteplase before EVT modestly increased intracranial hemorrhage—particularly parenchymal hematoma—yet ICH risk must be balanced against IVT-associated improvements in re
A nationwide Chinese registry analysis reveals no overall benefit of intravenous alteplase in minor ischemic stroke but suggests select subgroups, especially those with disabling symptoms or higher NIHSS scores, may experience improved func
THEIA trial evaluated intravenous alteplase against oral aspirin in acute CRAO within 4.5 hours; no significant visual improvement difference was found, emphasizing the need for further research and meta-analyses to clarify thrombolysis ben
The HOPE trial demonstrates that intravenous alteplase administered 4.5 to 24 hours after ischemic stroke onset improves functional independence in patients with salvageable brain tissue, despite increased risk of symptomatic intracranial h
The HOPE randomized trial shows that CT‑perfusion–selected patients treated with intravenous alteplase at 4.5–24 hours (no planned thrombectomy) had higher 90‑day functional independence (40.3% vs 26.3%), with increased symptomatic intracra